CUMYL-NBMINACA
Jump to navigation
Jump to search
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C25H29N3O |
Molar mass | 387.527 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-NBMINACA (SGT-152, Cumyl-BC[2.2.1]HpMINACA) is a synthetic cannabinoid compound first reported in a 2013 patent,[1] but not identified as a designer drug until 2021, being identified by a forensic laboratory in Germany in February 2021.[2][3]
See also
References
- ^ WO 2014167530, Bowden MJ, Williamson PB, "Cannabinoid compounds", issued 11 April 2013
- ^ Pulver B, Riedel J, Schönberger T, Pütz M, Schäper J, Kunert N, et al. (December 2021). "Comprehensive structural characterisation of the newly emerged synthetic cannabimimetics Cumyl-BC [2.2. 1] HpMeGaClone, Cumyl-BC [2.2. 1] HpMINACA, and Cumyl-BC [2.2. 1] HpMICA featuring a norbornyl methyl side chain". Forensic Chemistry. 26: 100371. doi:10.1016/j.forc.2021.100371. S2CID 243179410.
- ^ "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System" (PDF). June 2022.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cannabinoids
- Indazolecarboxamides
- All stub articles
- Cannabinoid stubs